Changes in erythroblast morphology as an index of response to cyanocobalamin in patients with megaloblastic anaemia.
Fifty-three patients with megaloblastic anaemia treated with  cyanocobalamin and folic acid have been studied. Repeat marrow examination was found to be of value in assessing response to treatment. The early improvement in marrow morphology in patients with pernicious anaemia was greater with 1000 mug than with 5 mug doses of cyanocobalamin. The effect of folate deficiency in delaying marrow response to cyanocobalamin in patients with pernicious anaemia is described and combined cyanocobalamin and folic acid treatment was found to be more effective than either alone. The response to large doses of cyanocobalamin in folate deficient patients was unrelated to the initial serum vitamin B12 level.
D000328:Adult; D000368:Aged; D000748:Anemia, Macrocytic / Q000188:drug therapy*; D000749:Anemia, Megaloblastic / Q000097:blood / Q000188:drug therapy*; D001856:Bone Marrow Examination; D002986:Clinical Trials as Topic; D004900:Erythroblasts / Q000473:pathology*; D004912:Erythrocytes / Q000473:pathology*; D005260:Female; D005492:Folic Acid / Q000097:blood / Q000627:therapeutic use; D005494:Folic Acid Deficiency / Q000188:drug therapy; D006801:Humans; D007501:Iron / Q000097:blood; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014805:Vitamin B 12 / Q000097:blood / Q000627:therapeutic use*
D005492:Folic Acid; D007501:Iron; D014805:Vitamin B 12